 Macrophages play important roles in the development of chronic liver diseases such as cirrhosis. Activating these cells with a specific drug can reduce inflammation and promote the transition of macrophages from a pro-inflammatory M1 state to an anti-inflammatory M2 state. This drug, called DGNSGW, is composed of graphene nanostars linked to a low dose of a paragonist. When administered to mice with liver fibrosis, it successfully activates par in macrophages, reduces inflammation, and promotes extracellular matrix remodeling. These results suggest that DGNSGW could be used as a potential therapy for treating liver fibrosis. This article was authored by Elas Moreno-Lancita, Miria Madronobosh, Blanca Simon-Codina, and others.